Beam Therapeutics INC

Beam Therapeutics announced second quarter 2026 financial results, highlighting progress in its AATD, PKU, and SCD programs, with a strong cash runway extending into mid-2029.

Beam Therapeutics Inc. announced the voting results from its 2026 annual meeting of stockholders, including the election of directors and ratification of its independent auditor.

Beam Therapeutics reported Q1 2026 results, highlighting clinical advancements in genetic diseases and hematology, with a strong cash position extending runway to mid-2029.

Beam Therapeutics ensures continued access to critical base editing patent rights through a new direct license with Kobe University following the dissolution of Bio Palette Co., Ltd.

Beam Therapeutics announced a new $500 million financing agreement with Sixth Street, expanded its pipeline with a new PKU program, and reported improved Q4 and full-year 2025 financial results.

Beam Therapeutics entered a standby license agreement with Kobe University and Bio Palette, ensuring continued access to critical gene-editing patents.

Beam Therapeutics reports on advancements in its gene editing therapies for sickle cell disease and AATD, alongside a substantial net loss and ongoing need for capital.

Beam Therapeutics reports a significant increase in license and collaboration revenue in Q1 2026, alongside a reduction in net loss, driven by milestone achievements and strategic financing.

Beam Therapeutics reported an increased net loss in Q3 2025 due to higher R&D expenses, despite positive clinical updates for its BEAM-101 and BEAM-302 programs and a significant capital raise.

Beam Therapeutics reports progress in its clinical trials for sickle cell disease and AATD, alongside a strong cash position, despite increased operating losses.

Beam Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in clinical trials and strategic collaborations.

Beam Therapeutics' Q3 2024 report details financial results, clinical trial progress, and strategic advancements in their gene editing programs.

Beam Therapeutics reported positive Phase 1/2 clinical data for its sickle cell disease candidate, risto-cel, and secured a $500 million credit facility, while continuing to advance its broad gene editing pipeline.

Beam Therapeutics advances its precision genetic medicine platform, expecting initial clinical data for BEAM-302 and BEAM-301 in the first half of 2025 and dosing 30 patients in the BEACON trial by mid-2025.

Beam Therapeutics has amended its lease agreement for its Durham, North Carolina facility, finalizing the base rent and addressing other terms.

Amy Simon, Chief Medical Officer of Beam Therapeutics Inc., sold 16,667 shares of common stock on July 27, 2026 for $25.74 per share.

Beam Therapeutics Chief Medical Officer Amy Simon sold 373 shares of common stock on June 30, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Beam Therapeutics CEO John M. Evans reports transactions involving the exercise of stock options and sale of common stock, executed under a pre-arranged trading plan.

FMR LLC, a significant holder, disclosed transactions involving Beam Therapeutics Inc. (BEAM) common stock on June 25th and 26th, 2026.

Director Christi Shaw was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Director Kathleen E. Walsh was granted 19,676 stock options in Beam Therapeutics Inc. as part of standard equity compensation.

Beam Therapeutics Inc. has issued its 2026 proxy statement, outlining the agenda for its upcoming annual meeting of stockholders to be held on June 3, 2026.

Beam Therapeutics will hold its annual stockholder meeting virtually on June 5, 2024.

Beam Therapeutics will hold its 2025 annual meeting of stockholders virtually on June 4, 2025, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.

Beam Therapeutics will hold its annual stockholder meeting virtually on June 5, 2024, to vote on director election, auditor ratification, and executive compensation.

Beam Therapeutics will hold its 2024 annual meeting of stockholders virtually on June 5, 2024, to vote on the election of a director, ratification of the independent accounting firm, and executive compensation.

ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, confirming their beneficial ownership of 9.95% of Beam Therapeutics Inc. common stock as of June 30, 2026.

Farallon Capital Management, L.L.C. and associated entities have reported beneficial ownership of 9.99% of Beam Therapeutics Inc.'s common stock, as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership of 5.02% in Beam Therapeutics Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G for Beam Therapeutics Inc., reporting 0% beneficial ownership due to an internal corporate realignment.

State Street Corporation has reported a 5.2% beneficial ownership stake in Beam Therapeutics Inc., holding over 5.2 million common shares.

Farallon Capital Management and its affiliates updated their beneficial ownership in Beam Therapeutics Inc. to 9.99%, reflecting internal management changes.